JP2010520881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520881A5 JP2010520881A5 JP2009552899A JP2009552899A JP2010520881A5 JP 2010520881 A5 JP2010520881 A5 JP 2010520881A5 JP 2009552899 A JP2009552899 A JP 2009552899A JP 2009552899 A JP2009552899 A JP 2009552899A JP 2010520881 A5 JP2010520881 A5 JP 2010520881A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- day
- treatment
- agent according
- wild type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 102100020873 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010029488 Nodular melanoma Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 201000000292 clear cell sarcoma Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- -1 hotemustine Chemical compound 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 150000003893 lactate salts Chemical class 0.000 claims 1
- 229960002247 lomustine Drugs 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000003731 mucosal melanoma Diseases 0.000 claims 1
- 201000000032 nodular malignant melanoma Diseases 0.000 claims 1
- 208000016450 non-cutaneous melanoma Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 229960001052 streptozocin Drugs 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- MWLBMGPQZJDFKZ-UHFFFAOYSA-N 23491-48-7 Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(N)=C1 MWLBMGPQZJDFKZ-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- ANQVKHGDALCPFZ-UHFFFAOYSA-N ethyl 2-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]acetate Chemical compound C1=C2NC(CC(=O)OCC)=NC2=CC=C1N1CCN(C)CC1 ANQVKHGDALCPFZ-UHFFFAOYSA-N 0.000 description 2
- HYMXUYQKXCHWDC-UHFFFAOYSA-N ethyl 3-ethoxy-3-iminopropanoate;hydrochloride Chemical compound Cl.CCOC(=N)CC(=O)OCC HYMXUYQKXCHWDC-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000694440 Colpidium aqueous Species 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89404607P | 2007-03-09 | 2007-03-09 | |
| US91140607P | 2007-04-12 | 2007-04-12 | |
| PCT/US2008/056122 WO2008112509A1 (en) | 2007-03-09 | 2008-03-07 | Treatment of melanoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520881A JP2010520881A (ja) | 2010-06-17 |
| JP2010520881A5 true JP2010520881A5 (https=) | 2011-04-21 |
Family
ID=39500684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552899A Pending JP2010520881A (ja) | 2007-03-09 | 2008-03-07 | 黒色腫の処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100086518A1 (https=) |
| JP (1) | JP2010520881A (https=) |
| KR (1) | KR20090119768A (https=) |
| AU (1) | AU2008226582B2 (https=) |
| BR (1) | BRPI0808714A2 (https=) |
| CA (1) | CA2679268A1 (https=) |
| CL (1) | CL2008000681A1 (https=) |
| MX (1) | MX2009009574A (https=) |
| RU (1) | RU2009136669A (https=) |
| TW (1) | TW200843766A (https=) |
| WO (1) | WO2008112509A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2933702A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| TWI410418B (zh) | 2009-04-29 | 2013-10-01 | Ind Tech Res Inst | 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法 |
| EP2432451A2 (en) * | 2009-05-20 | 2012-03-28 | Children's Medical Center Corporation | Compositions for the treatment of metastatic cancer and methods of use thereof |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
| US8551479B2 (en) * | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| CN105683188B (zh) | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| US10495138B2 (en) | 2014-09-29 | 2019-12-03 | Hewlett-Packard Development Company, L.P. | Hinge assembly with compressible sleeve |
| JP6585167B2 (ja) | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| EP3103450A1 (en) | 2015-06-12 | 2016-12-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | None-hydrophobic compounds for use in treating metastasis and/or cartilage defect |
| BR112019024556A2 (pt) | 2017-05-24 | 2020-06-23 | Novartis Ag | Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer |
| CN108610293B (zh) * | 2018-06-15 | 2020-08-04 | 南京工业大学 | 一种采用微通道反应装置制备多韦替尼中间体的方法 |
| WO2024097855A2 (en) * | 2022-11-03 | 2024-05-10 | University Of Florida Research Foundation, Incorporated | Identification of small molecules that recruit and activate rnase l |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003290699B2 (en) * | 2002-11-13 | 2009-08-27 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
| US7691905B2 (en) * | 2002-12-24 | 2010-04-06 | New York University | Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA) |
| CN102225926A (zh) * | 2003-11-07 | 2011-10-26 | 诺华疫苗和诊断公司 | 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐 |
| JP2009543810A (ja) * | 2006-07-13 | 2009-12-10 | ザイモジェネティクス， インコーポレイテッド | インターロイキン２１およびチロシンキナーゼ阻害剤の併用治療の方法 |
| KR20090046893A (ko) * | 2006-07-28 | 2009-05-11 | 노파르티스 아게 | 흑색종에서 치료학적 반응에 대한 조기 지표로서의 흑색종 억제 활성 (ｍｉａ) 단백질의 용도 |
-
2008
- 2008-03-07 CA CA002679268A patent/CA2679268A1/en not_active Abandoned
- 2008-03-07 RU RU2009136669/15A patent/RU2009136669A/ru not_active Application Discontinuation
- 2008-03-07 KR KR1020097018743A patent/KR20090119768A/ko not_active Withdrawn
- 2008-03-07 MX MX2009009574A patent/MX2009009574A/es not_active Application Discontinuation
- 2008-03-07 AU AU2008226582A patent/AU2008226582B2/en not_active Ceased
- 2008-03-07 US US12/530,231 patent/US20100086518A1/en not_active Abandoned
- 2008-03-07 JP JP2009552899A patent/JP2010520881A/ja active Pending
- 2008-03-07 TW TW097108226A patent/TW200843766A/zh unknown
- 2008-03-07 WO PCT/US2008/056122 patent/WO2008112509A1/en not_active Ceased
- 2008-03-07 CL CL200800681A patent/CL2008000681A1/es unknown
- 2008-03-07 BR BRPI0808714-8A patent/BRPI0808714A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520881A5 (https=) | ||
| DE60221804T2 (de) | Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung | |
| JP2006511563A5 (https=) | ||
| JP2006523194A5 (https=) | ||
| CN117045653A (zh) | 与毒性醛相关的疾病和治疗 | |
| JP2018517774A (ja) | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 | |
| FI3982963T3 (fi) | Koostumus, johon sisältyy pridopidiini ja sen analogi, huntingtonin taudin ja sen oireitten hoitoa varten | |
| RU2013113634A (ru) | Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств | |
| CN101031562A (zh) | 咪唑－5－羧酸类衍生物、制备方法及其应用 | |
| JP2009527509A5 (https=) | ||
| CN102827146B (zh) | 一种氟喹诺酮醛缩异烟腙及其制备方法和应用 | |
| JPS61210085A (ja) | 免疫調節剤として有効なイミダゾ〔４，５−ｆ〕キノリン | |
| CN113214275B (zh) | 吡喃并咔唑生物碱类衍生物及其治疗神经系统疾病的用途 | |
| JP2006516565A (ja) | 治療薬を製造するための２−アミノ−２ｈ−キナゾリン誘導体の使用 | |
| JP2009502760A (ja) | 新規なロシグリタゾン塩 | |
| JP4837722B2 (ja) | 置換スルホキシド化合物、その調製方法、およびその使用方法 | |
| JP5290190B2 (ja) | イミダゾール−５−カルボン酸誘導体の塩、製造方法及びその医薬組成物 | |
| JPH11506753A (ja) | 平滑筋細胞増殖の阻害薬としてのスチリルベンゾイミダゾール誘導体 | |
| CN108727341B (zh) | 一种吡咯取代吲哚酮类衍生物或其药学上可接受的盐、及它们的制备方法和用途 | |
| CN1288377A (zh) | 钾通道激活剂 | |
| WO2011151701A1 (en) | 6 - methyl - 4 - phenyl - 5 - ( phenyl or cycloalkyl) carbamoyl - 1,2,3, 4 - tetrahydropyrimidin- 2 - one derivatives as antitubercular agents | |
| CN103153990B (zh) | 新型吡啶基苯并噁嗪衍生物、包含其的药物组合物及其用途 | |
| CN103304556B (zh) | 含有苯并吡喃的希夫碱类化合物、其制备方法和用途 | |
| WO2016153242A1 (ko) | 중추신경계 질환의 치료 또는 예방용 약학 조성물 | |
| JPWO1996000213A1 (ja) | ピリジン誘導体 |